EUVIMEDEUVIMED entdecken
Crossref

Current use of aflibercept 8 mg (eylea HD) in retinal diseases

Mehmet Çıtırık

Archives of Ophthalmological Research · 2024

DOI: 10.51271/aor-0003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Ophthalmological Research, 2024. Verfasst von Mehmet Çıtırık.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aflibercept 8 mg (Eylea HD) has emerged as a pivotal agent in the treatment of retinal diseases and has begun to showcase its efficacy and innovation in the field of ophthalmology. This article delves into the current use of aflibercept 8 mg, exploring its applications, mechanisms of action, and impact on the treatment landscape for various retinal conditions. This review provides an overview of recent clinical studies and highlights the key findings and advancements associated with the use of 8 mg aflibercept.

Zitieren

APA

Çıtırık, M. (2024). Current use of aflibercept 8 mg (eylea HD) in retinal diseases. Archives of Ophthalmological Research. https://doi.org/10.51271/aor-0003

Vancouver

Çıtırık M. Current use of aflibercept 8 mg (eylea HD) in retinal diseases. Archives of Ophthalmological Research. 2024. doi:10.51271/aor-0003

BibTeX
@article{trk2024,
  author = {Çıtırık, Mehmet},
  title = {Current use of aflibercept 8 mg (eylea HD) in retinal diseases},
  journal = {Archives of Ophthalmological Research},
  year = {2024},
  doi = {10.51271/aor-0003}
}
Kostenlos starten →